In CRC, patients with upregulated expression of CYP26A1 have a decreased fraction of CD8+ T cells and probability of OS, indicating that targeting retinoic acid metabolism holds promise as a therapeutic approach for treating CRC [31, 32]. Here, CD8A is linked to colorectal carcinoma.